Study offers treatment hope for Rett syndrome

The symptoms of a severe autism spectrum disorder affecting at least 10,000 children in the UK could be reversed following research by Scottish scientists.

Rett syndrome, which can leave children wheelchair bound, unable to speak and suffering from breathing difficulties, has until now been considered an untreatable neurological disorder.

But experts have now been able to make symptoms disappear in mice by activating a specific gene.

The research, led by the University of Edinburgh in collaboration with the University of Glasgow, focused on the behaviour of the MECP2 gene that causes the syndrome to develop. They found that when this gene was activated in mice, which had previously been born with it switched off, symptoms such as breathing and mobility difficulties ceased. Over a four week period, the mice often became undistinguishable from healthy counterparts.

The findings give impetus to ways of treating Rett syndrome, which mainly affects girls. Further research may also show that the results could apply to other autism spectrum disorders.

Prof Adrian Bird, Director of the Wellcome Trust Centre for Cell Biology at the University of Edinburgh, led the research and first discovered the MECP2 gene in 1990. He said: "The results we came across were entirely unexpected. Until now it had been thought that Rett syndrome is irrevocable, but our findings show that the damage to nerve cell function is, in fact, reversible. This gives a major boost to the search for treatments or a potential cure."

The research, which is published online by the journal Science in Science Express, was funded by the Wellcome Trust, Rett Syndrome Association UK (with support from Jeans for Genes) and the US-based Rett Syndrome Research Foundation.

Although Rett Syndrome is present at birth, it becomes more evident during the second year. It is believed to be the second most common cause of severe and profound learning disability in girls.

Potential treatment, following on from the research, could range from overriding the mutated version of MECP2 with the activation of a healthy version of the gene. Alternatively, therapy could focus on drug treatment to inhibit the action of proteins expressed as a result of a MECP2 mutation.

Chris James, director of Rett Syndrome Association UK, said: "The Rett Syndrome Association UK is extremely delighted to hear about the results of Professor Bird's research. This is a very significant step on the road for future therapeutic approaches to Rett syndrome and, whilst the work in this area is still at an early stage, it will give hope to those families affected by Rett syndrome. It is particularly pleasing for us that we have been able to help fund this research that could have such a positive benefit for people with Rett syndrome, their families and carers."

Source: University of Edinburgh

Related stories:

Critical mass in rare diseases -- an innovative Internet approach
The internet is emerging as a valuable tool for scientists to gather data for critical research into rare diseases. Disability researcher, Dr Helen Leonard, from Australia's Institute for Child Health Research, said its InterRett online database had greatly expanded research into the neurological disorder Rett syndrome, which affects 1 in 8500 girls.
Researchers find differences in swallowing mechanism of Rett syndrome patients
Researchers at Wake Forest University Baptist Medical Center have found that the reflux and swallowing problems that are common symptoms in patients with Rett syndrome and other neurological impairments, may be caused by a different mechanism than they are in healthy individuals. The finding leaves researchers to wonder if these patients truly benefit from anti-reflux surgery commonly performed in these children.
Researchers link early stem cell mutation to autism
In a breakthrough scientific study published today in the Proceedings of the National Academy of Sciences, scientists at the Burnham Institute for Medical Research have shown that neural stem cell development may be linked to Autism. The study demonstrated that mice lacking the myocyte enhancer factor 2C (MEF2C) protein in neural stem cells had smaller brains, fewer nerve cells and showed behaviors similar to those seen in humans with a form of autism known as Rett Syndrome.
Genetic analysis reveals range of Rett syndrome
The first comprehensive analysis of the clinical effects of genetic mutations involved in Rett syndrome will enable affected families to receive a more accurate indication of their child’s prognosis.
Rett syndrome research reveals high fracture risk
Researchers at Perth’s Telethon Institute for Child Health Research have found that girls and young women with Rett syndrome are nearly four times more likely to suffer a fracture.
Study finds first-ever genetic animal model of autism
By introducing a gene mutation in mice, investigators have created what they believe to be the first accurate model of autism not associated with a broader neuropsychiatric syndrome, according to research presented at the American College of Neuropsychopharmacology annual meeting.
Insights into activity-dependent neuronal growth through RSRF-supported research
Brain-derived neurotrophic factor (BDNF) has been a subject of keen interest in neuroscientific circles for several years, turning up in studies of conditions ranging from central hypoventilation syndrome to obsessive-compulsive disorder, depression, bipolar disorder and schizophrenia -- a range of disorders uncannily parallel to those produced by mutations in the "Rett gene," MeCP2.
Study: Rett syndrome can strike males
Australian researchers say they've discovered Rett Syndrome can strike males, as well as females.

News discussion:

Medicine & Health news